Table 4.
Male | Female | |||||
---|---|---|---|---|---|---|
N | β | 95% CI | N | β | 95% CI | |
Newborn Telomere Length (N = 291) | ||||||
Overalla | 145 | 0.04 | (-0.03, 0.12) | 146 | 0.01 | (-0.07, 0.09) |
PFASb | 145 | 0.01 | (-0.05, 0.07) | 146 | 0.00 | (-0.07, 0.07) |
PBDEsc | 145 | 0.03 | (-0.02, 0.07) | 146 | 0.02 | (-0.03, 0.08) |
Maternal Telomere Length (N = 109) | ||||||
Overalla | 52 | 0.11 | (0.00, 0.23) | 57 | -0.01 | (-0.09, 0.07) |
PFASb | 52 | 0.14 | (0.01, 0.27) | 57 | 0.03 | (-0.03, 0.09) |
PBDEsc | 52 | -0.02 | (-0.08, 0.05) | 57 | -0.04 | (-0.09, 0.02) |
Abbreviations: CI Confidence interval
Adjusted for maternal age, race/ethnicity, education, parity, and pre-pregnancy body mass index
Note: Beta estimates are interpreted as the effect on telomere length of increasing every exposure in the mixture by one quantile. There are 326 pregnant participants, of which there are 76 maternal–fetal unit pairs. Infant sex was missing for one participant
aAdjusted for maternal age, race/ethnicity, education, parity, and pre-pregnancy body mass index
bMixture effect is for only PFAS, adjusted for maternal age, race/ethnicity, education, parity, pre-pregnancy body mass index, and PBDEs
cMixture effect is for only PBDEs, adjusted for maternal age, race/ethnicity, education, parity, pre-pregnancy body mass index, and PFAS